110 related articles for article (PubMed ID: 2593379)
1. A new antitumor antibiotic, FK973: its metabolism in the blood and the antitumor effects of its metabolites on experimental models.
Masuda K; Suzuki A; Nakamura T; Takagaki S; Noda K; Shimomura K; Noguchi H; Shibayama F
Jpn J Pharmacol; 1989 Oct; 51(2):219-26. PubMed ID: 2593379
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
3. Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.
Masuda K; Nakamura T; Shimomura K
Jpn J Pharmacol; 1990 Aug; 53(4):463-72. PubMed ID: 2214370
[TBL] [Abstract][Full Text] [Related]
4. Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro.
Nakamura T; Masuda K; Matsumoto S; Oku T; Manda T; Mori J; Shimomura K
Jpn J Pharmacol; 1989 Mar; 49(3):317-24. PubMed ID: 2501546
[TBL] [Abstract][Full Text] [Related]
5. Interstrand DNA-DNA and DNA-protein cross-links by a new antitumor antibiotic, FK973, in L1210 cells.
Masuda K; Nakamura T; Mizota T; Mori J; Shimomura K
Cancer Res; 1988 Sep; 48(18):5172-7. PubMed ID: 3409243
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of a new antitumor antibiotic, FK973, in malignant glioma.
Moriuchi S; Shimizu K; Yamada M; Mabuchi E; Tamura K; Park KC; Hayakawa T
Anticancer Res; 1991; 11(6):2079-84. PubMed ID: 1776843
[TBL] [Abstract][Full Text] [Related]
7. FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.
Naoe Y; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Kawamura I; Miyayasu K; Manda T; Shimomura K
Cancer Chemother Pharmacol; 1998; 42(1):31-6. PubMed ID: 9619755
[TBL] [Abstract][Full Text] [Related]
8. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay.
Horiuchi N; Nakagawa K; Sasaki Y; Minato K; Fujiwara Y; Nezu K; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 1988; 22(3):246-50. PubMed ID: 2842080
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of FK973 against human oral and breast cancer cells.
Wu JZ; Adachi I; Watanabe T
Chin Med J (Engl); 1991 Oct; 104(10):834-7. PubMed ID: 1661225
[TBL] [Abstract][Full Text] [Related]
10. A new antitumor antibiotic, FR-900482. III. Antitumor activity in transplantable experimental tumors.
Shimomura K; Hirai O; Mizota T; Matsumoto S; Mori J; Shibayama F; Kikuchi H
J Antibiot (Tokyo); 1987 May; 40(5):600-6. PubMed ID: 3610819
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor activity of FK973 for malignant gliomas and its assessment for normal brain cells].
Moriuchi S; Shimizu K; Yamada M; Mabuchi E; Tamura K; Park K; Hayakawa T; Mogami H
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2774-80. PubMed ID: 2074387
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).
Ho DH; Pazdur R; Brown NS; Covington WP; Raber MN; Krakoff IH
Anticancer Res; 1993; 13(2):343-6. PubMed ID: 8517646
[TBL] [Abstract][Full Text] [Related]
13. Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent.
Schurig JE; Rose WC; Kamei H; Nishiyama Y; Bradner WT; Stringfellow DA
Invest New Drugs; 1990 Feb; 8(1):7-15. PubMed ID: 2345072
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of spergualin, a novel antitumor antibiotic.
Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Oct; 39(10):1461-6. PubMed ID: 3781914
[TBL] [Abstract][Full Text] [Related]
16. Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.
Schurig JE; Bradner WT; Basler GA; Rose WC
Invest New Drugs; 1989 Jul; 7(2-3):173-8. PubMed ID: 2793369
[TBL] [Abstract][Full Text] [Related]
17. A new antitumor antibiotic, FR900840. III. Antitumor activity against experimental tumors.
Nishimura M; Nakada H; Kawamura I; Mizota T; Shimomura K; Nakahara K; Goto T; Yamaguchi I; Okuhara M
J Antibiot (Tokyo); 1989 Apr; 42(4):553-7. PubMed ID: 2542208
[TBL] [Abstract][Full Text] [Related]
18. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Ueda H; Manda T; Matsumoto S; Mukumoto S; Nishigaki F; Kawamura I; Shimomura K
J Antibiot (Tokyo); 1994 Mar; 47(3):315-23. PubMed ID: 8175484
[TBL] [Abstract][Full Text] [Related]
19. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
20. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action.
Nakajima H; Hori Y; Terano H; Okuhara M; Manda T; Matsumoto S; Shimomura K
J Antibiot (Tokyo); 1996 Dec; 49(12):1204-11. PubMed ID: 9031665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
